NASDAQ:IKT Inhibikase Therapeutics (IKT) Stock Price, News & Analysis $1.52 -0.01 (-0.65%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$1.52 -0.01 (-0.33%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Inhibikase Therapeutics Stock (NASDAQ:IKT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IKT alerts:Sign Up Key Stats Today's Range$1.49▼$1.5850-Day Range$1.44▼$2.5052-Week Range$1.40▼$2.61Volume333,111 shsAverage Volume629,775 shsMarket Capitalization$213.21 millionP/E RatioN/ADividend YieldN/APrice Target$4.75Consensus RatingModerate Buy Company Overview Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson’s disease and other neurodegenerative disorders. The company’s research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration. Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson’s disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.AI Generated. May Contain Errors. Read More Inhibikase Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreIKT MarketRank™: 2.10120292887 of 5 starsInhibikase Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 661st out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingInhibikase Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 3 strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialInhibikase Therapeutics has a consensus price target of $4.75, representing about 212.5% upside from its current price of $1.52.Amount of Analyst CoverageInhibikase Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Inhibikase Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Inhibikase Therapeutics are expected to decrease in the coming year, from ($0.43) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibikase Therapeutics is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibikase Therapeutics is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibikase Therapeutics has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.99% of the float of Inhibikase Therapeutics has been sold short.Short Interest Ratio / Days to CoverInhibikase Therapeutics has a short interest ratio ("days to cover") of 28.59, which indicates bearish sentiment.Change versus previous monthShort interest in Inhibikase Therapeutics has recently decreased by 1.01%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInhibikase Therapeutics does not currently pay a dividend.Dividend GrowthInhibikase Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.61 News SentimentInhibikase Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Inhibikase Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Inhibikase Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.10% of the stock of Inhibikase Therapeutics is held by insiders.Percentage Held by Institutions3.81% of the stock of Inhibikase Therapeutics is held by institutions.Read more about Inhibikase Therapeutics' insider trading history. Receive IKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IKT Stock News HeadlinesInhibikase Therapeutics (NASDAQ:IKT) Earns Neutral Rating from Chardan CapitalNovember 14 at 4:41 AM | americanbankingnews.comInhibikase Therapeutics (NASDAQ:IKT) Stock Moved Up to Sell by Wall Street ZenNovember 14 at 2:05 AM | americanbankingnews.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks. | Weiss Ratings (Ad)Inhibikase Therapeutics' (IKT) Buy Rating Reaffirmed at HC WainwrightNovember 13 at 4:15 AM | americanbankingnews.comAnalysts Offer Insights on NA Companies: Lucid Group (LCID) and Inhibikase Therapeutics (IKT)November 12 at 3:22 PM | theglobeandmail.comInhibikase Secures 28 Country Approvals For Phase 3 PAH Trial; H1 2027 Safety Update PlannedNovember 11, 2026 | rttnews.comInhibikase Therapeutics (IKT) Q3 2026: EPS Beat Driven by a Larger Share CountNovember 11, 2026 | 247wallst.comInhibikase Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10, 2026 | marketscreener.comMSee More Headlines IKT Stock Analysis - Frequently Asked Questions How have IKT shares performed this year? Inhibikase Therapeutics' stock was trading at $2.05 at the beginning of 2026. Since then, IKT shares have decreased by 25.9% and is now trading at $1.52. How were Inhibikase Therapeutics' earnings last quarter? Inhibikase Therapeutics, Inc. (NASDAQ:IKT) released its earnings results on Tuesday, November, 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. When did Inhibikase Therapeutics' stock split? Inhibikase Therapeutics's stock reverse split on the morning of Friday, June 30th 2023.The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did Inhibikase Therapeutics IPO? Inhibikase Therapeutics (IKT) raised $20 million in an IPO on Wednesday, December 23rd 2020. The company issued 1,800,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. Who are Inhibikase Therapeutics' major shareholders? Top institutional investors of Inhibikase Therapeutics include State Street Corp (1.59%), Nantahala Capital Management LLC (1.39%), Alps Advisors Inc. (0.13%) and Abel Hall LLC (0.04%). View institutional ownership trends. How do I buy shares of Inhibikase Therapeutics? Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inhibikase Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibikase Therapeutics investors own include Palantir Technologies (PLTR), Altria Group (MO), Energy Transfer (ET), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC) and ServiceNow (NOW). Company Calendar Last Earnings11/10/2026Today11/15/2026Jefferies Global Healthcare Conference11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 IKT's financial health is in the Yellow zone, according to TradeSmith. IKT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:IKT Previous SymbolNYSE:IKT CIK1750149 Webinhibikase.com Phone(678) 392-3419FaxN/AEmployees35Year Founded2008Price Target and Rating Average Price Target for Inhibikase Therapeutics$4.75 High Price Target$8.00 Low Price Target$1.50 Potential Upside/Downside+212.5%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-40.53% Return on Assets-38.44% Debt Debt-to-Equity RatioN/A Current Ratio15.34 Quick Ratio15.82 Sales & Book Value Annual Sales$260 thousand Price / Sales820.04 Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book1.13Miscellaneous Outstanding Shares140,270,000Free Float130,311,000Market Cap$213.21 million OptionableN/A Beta0.94 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:IKT) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredSHOCKING! Prediction caught on cameraNewly released footage shows James Altucher pulling a document out of a briefcase on camera. It is a document ...Paradigm Press | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
